Friday, June 3, 2011

Novartis growth could fill Emeryville hole

Bayer’s decision to pull out of Emeryville leaves a mark — first and foremost on the 540 jobs that will be lost over the next two years when the pharmaceutical company outsources production of its multiple sclerosis drug Betaseron.
And while Novartis isn’t ready to shed any light on its plans for the building, it’s providing a possible clue down the block. Novartis is soon to begin demolishing the five-story former lab building, known as Building M.

No comments:

Post a Comment